Literature DB >> 19725152

Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients.

Jin Li1, Lu-Nan Yan, Jian Yang, Zhe-Yu Chen, Bo Li, Yong Zeng, Tian-Fu Wen, Ji-Chun Zhao, Wen-Tao Wang, Jia-Yin Yang, Ming-Qing Xu, Yu-Kui Ma.   

Abstract

AIM: To identify prognostic factors of patients with hepatocellular carcinoma (HCC), who were treated by orthotopic liver transplantation (OLT).
METHODS: From January 2000 to October 2006, 165 patients with HCC underwent OLT. Various clinicopathological risk factors for actuarial and recurrence-free survival were identified using the Kaplan-Meier method with the log-rank test. The Cox proportional hazards model was used to identify independently predictive factors for actuarial and recurrence-free survival, which were used to propose new selection criteria. We compared the outcome of the subgroup patients meeting different criteria. Survival analysis was performed using the Kaplan-Meier method with the log-rank test.
RESULTS: The median follow-up was 13.0 mo (2.8-69.5 mo). Overall, 1-, 2-, 3- and 5-year actuarial survival was 73.3%, 45.6%, 35.4% and 32.1%, respectively. One-, 2-, 3- and 5-year overall recurrence-free survival was 67.0%, 44.3%, 34.5% and 34.5%, respectively. In univariate analysis, number of tumors, total tumor size, lobar distribution, differentiation, macrovascular invasion, microvascular invasion, capsulation of the tumor, and lymph node metastasis were found to be associated significantly with actuarial and tumor-free survival. By means of using the multivariate Cox proportional hazards model, total tumor size and macrovascular invasion were found to be independent predictors of actuarial and tumor-free survival. When the selection criteria were expanded into the proposed criteria, there was no significant difference in 1-, 2-, 3- and 5-year actuarial and tumor-free survival of the 49 patients who met the proposed criteria (97.6%, 82.8%, 82.8% and 82.8%, and 90.7%, 82.8%, 68.8% and 68.8%, respectively) compared with that of patients who met the Milan or University of California, San Francisco (UCSF) criteria.
CONCLUSION: Macrovascular invasion and total tumor diameter are the strongest prognostic factors. The proposed criteria do not adversely affect the outcome of liver transplantation for HCC, compared with the Milan or UCSF criteria.

Entities:  

Mesh:

Year:  2009        PMID: 19725152      PMCID: PMC2738814          DOI: 10.3748/wjg.15.4170

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Liver organ allocation for hepatocellular carcinoma: are we sure?

Authors:  J Wallis Marsh; Igor Dvorchik
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

3.  Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?

Authors:  J W Marsh; I Dvorchik; C A Bonham; S Iwatsuki
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

4.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  J I Herrero; B Sangro; J Quiroga; F Pardo; M Herraiz; J A Cienfuegos; J Prieto
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

5.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 6.  Liver transplantation for hepatocellular carcinoma.

Authors:  A W Hemming; D R Nelson; A I Reed
Journal:  Minerva Chir       Date:  2002-10       Impact factor: 1.000

7.  Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.

Authors:  Sasan Roayaie; Jason S Frischer; Sukru H Emre; Thomas M Fishbein; Patricia A Sheiner; Max Sung; Charles M Miller; Myron E Schwartz
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

8.  Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience.

Authors:  S Roayaie; M B Haim; S Emre; T M Fishbein; P A Sheiner; C M Miller; M E Schwartz
Journal:  Ann Surg Oncol       Date:  2000-12       Impact factor: 5.344

9.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

10.  Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.

Authors:  Kirti Shetty; Kate Timmins; Colleen Brensinger; Emma E Furth; Sushil Rattan; Weijing Sun; Mark Rosen; Michael Soulen; Abraham Shaked; K Rajender Reddy; Kim M Olthoff
Journal:  Liver Transpl       Date:  2004-07       Impact factor: 5.799

View more
  16 in total

1.  Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.

Authors:  Guang-Qin Xiao; Jiu-Lin Song; Shu Shen; Jia-Yin Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

3.  Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.

Authors:  Ping Wan; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.

Authors:  Dong-Wei Xu; Ping Wan; Qiang Xia
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

5.  Predictors of Outcome of Living Donor Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Hazem Mohamed Zakaria; Ahmed N Sallam; Islam I Ayoub; Sherif M Saleh; Doha Maher; Hazem Omar; Mohamed Abou-Shady; Ibrahim A Salama; El-Sayed A Soliman; Khaled Abou El-Ella; Tarek M Ibrahim; Essam M Hammad
Journal:  Indian J Surg       Date:  2016-04-07       Impact factor: 0.656

Review 6.  Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma.

Authors:  Kohei Ogawa; Yasutsugu Takada
Journal:  Transl Gastroenterol Hepatol       Date:  2016-05-04

Review 7.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

8.  Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.

Authors:  Guang-Qin Xiao; Chang Liu; Da-Li Liu; Jia-Yin Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience.

Authors:  Ping Wan; Qiang Xia; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-30       Impact factor: 4.553

10.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.